Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.
PI3K Inhibitors have emerged as a popular treatment for hormone-receptor-positive breast cancers, improving progression-free survival rates for those with ER+ breast cancer.